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Oligomers of 40- or 42-mer amyloid β-protein (Aβ40, Aβ42) cause cognitive decline and synaptic dysfunction in Alzheimer’s
disease. We proposed the importance of a turn at Glu22 and Asp23 of Aβ42 to induce its neurotoxicity through the formation of
radicals.Recently,anoveldeletionmutantatGlu22(E22Δ)ofAβ42wasreportedtoaccelerateoligomerizationandsynaptotoxicity.
To investigate this mechanism, the eﬀects of the E22Δ mutation in Aβ42 and Aβ40 on the transformation of β-sheets, radical
production, and neurotoxicity were examined. Both mutants promoted β-sheet transformation and the formation of radicals,
while their neurotoxicity was negative. In contrast, E22P-Aβ42 with a turn at Glu22 and Asp23 exhibited potent neurotoxicity
along with the ability to form radicals and potent synaptotoxicity. These data suggest that conformational change in E22Δ-Aβ is
similar to that in E22P-Aβ42 but not the same, since E22Δ-Aβ42 exhibited no cytotoxicity, unlike E22P-Aβ42 and wild-type Aβ42.
1.Introduction
Alzheimer’s disease (AD) is characterized by amyloid depo-
sition in senile plaques that are mainly composed of 40- and
42-mer amyloid β-proteins (Aβ40 and Aβ42) [1, 2]. These
proteins are secreted from amyloid precursor protein (APP)
by two proteases, β-a n dγ-secretases [3]. Aβ42 plays a more
critical role in the pathogenesis of AD than Aβ40 because
of its stronger aggregative ability and neurotoxicity [3].
Oxidative stress is believed to contribute to neuronal loss in
AD[4–6];oneoftheproposedmechanismsofAβ42-induced
neurotoxicity is related to the radicalization at both Tyr10
and Met35 accompanied by the generation of hydrogen
peroxide [7, 8]. On the other hand, soluble oligomeric
assembly of Aβ causes cognitive impairment and synaptic
d y s f u n c t i o ni nA D[ 9, 10].
Our previous investigation using solid-state NMR to-
gether with systematic proline replacement proposed a toxic
conformer with a turn at positions 22 and 23 in Aβ42
aggregates and a nontoxic conformer with a turn at positions
25 and 26; the former showed a potent ability to aggregate,
formoligomers,andexhibitneurotoxicity[11].Theturnfor-
mation at positions 22 and 23 along with the neighboring β-
sheetstructureinthetoxicconformerofAβ42broughtTyr10
and Met35 close together to generate the S-oxidized radical
cation at Met35, the ultimate toxic radical species, through
oxidation by the phenoxy radical at Tyr10 produced by redox
reactions [7, 12]. The mutations of Aβ are concentrated at2 International Journal of Alzheimer’s Disease
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Figure 1: Aggregation proﬁles of E22Δ-Aβ40 and E22Δ-Aβ42 (25μM) after incubation at 37◦C. (a) Sedimentation assay estimated by HPLC
analysis after centrifugation. (b) Th-T ﬂuorescence assay. ◦,A β42;  ,A β40; •,E 2 2 Δ-Aβ42; ,E 2 2 Δ-Aβ40. (c) Western blotting without
incubation.
positions 21, 22, and 23; A21G (Flemish), E22G (Arctic),
E22Q (Dutch), E22K (Italian), and D23N (Iowa) types.
These mutations may play a pathological role in cerebral
amyloid angiopathy (CAA) or familial AD (FAD) because
these mutant proteins induced neuronal death in vitro more
potently than wild-type Aβ42 [13]. Thus, Glu22 and Asp23
in Aβ are considered to be key residues for neurotoxicity
through the formation of radicals.
Recently, Mori and coworkers reported that a novel
mutation, in which the Glu-22 residue is defective (E22Δ),
induced AD-type dementia without amyloid deposition, and
that in vitro E22Δ-Aβ42 favorably formed low-molecular
weight oligomers to inhibit long-term potentiation (LTP)
compared with Aβ42 [14] and to induce synaptic alteration
[15]. Therefore, the eﬀects of the deletion at Glu22 on the
secondarystructure,formationofradicals,andneurotoxicity
are interesting from the standpoint of discussing the role of
the Glu-22 residue of Aβ42 in the pathogenesis of AD.
This paper describes a comprehensive study of the
aggregative ability, secondary structure, radical-generating
activity, neurotoxicity in primary rat cortical neuronal cell
cultures, and the inhibitory activity of LTP of both E22Δ-
Aβ40 and E22Δ-Aβ42. These results were compared with
those of E22P-Aβ42 with a turn at positions 22 and 23.
2.MaterialsandMethods
2.1. Preparation of E22Δ-Aβ. E22Δ-Aβ40 and E22Δ-Aβ42
were synthesized by the method reported previously [16].
Their molecular weights were conﬁrmed by matrix-assisted
laserdesorption/ionizationtime-of-ﬂightmassspectrometry
(MALDI-TOF-MS):E22Δ-Aβ40(m/z:calcd:4201.76; found:International Journal of Alzheimer’s Disease 3
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Figure 2: CD spectra of E22Δ-Aβ40 and E22Δ-Aβ42 (25μM). (a) Aβ40, (b) E22Δ-Aβ40, (c) Aβ42, (d) E22Δ-Aβ42. Each Aβ (25μM) was
incubated in phosphate buﬀer at 37◦C for the following times: ,0h ;,4h ; ,8h ;◦,2 4h ;,48h.
4201.56 [M + H]+), E22Δ-Aβ42 (m/z: calcd: 4386.00; found:
4385.98 [M + H]+).
2.2. Sedimentation Assay. The aggregation kinetics of each
Aβ (25μM) was estimated with the sedimentation assay
usingHPLC.Theexperimentalprocedurewasdescribedelse-
where [13]. The area of absorption at 220nm was integrated
and expressed as a percentage of the control.
2.3. Thioﬂavin T (Th-T) Fluorescence Assay. Aggregative
ability of each Aβ (25μM) was evaluated by the Th-T
method developed by Naiki and Gejyo [17]. The mea-
surement was performed on a Multidetection Microplate
Reader powerscan HT (Dainippon Sumitomo Pharma) at
roomtemperature,asdescribedelsewhere[13].Fluorescence
intensity was measured at 450nm excitation and 482nm
emission.
2.4. Western Blotting. Gel electrophoresis using 10–20%
Tricine gel (Invitrogen, Carlsbad, CA) and Western blots
analysis were carried out according to the manufacturer’s
protocol. The experimental procedure was described else-
where [12]. Brieﬂy, each Aβ was dissolved in 0.1% NH4OH
at 250μM. After a 10-fold dilution by 50mM sodium phos-
phate containing 100mM NaCl at pH 7.4, the resultant
peptide solution (25μM) was incubated for 0, 2, or 4hr at4 International Journal of Alzheimer’s Disease
WT-Aβ40 (1)
(a)
E22Δ-Aβ40 (2.5)
(b)
WT-Aβ42 (2.1)
(c)
E22Δ-Aβ42 (2.4)
(d)
Figure 3: ESR spectra of E22Δ-Aβ40 and E22Δ-Aβ42 (100μM)
after 48-hr incubation at 37◦C. (a) Aβ40, (b) E22Δ-Aβ40, (c) Aβ42,
(d) E22Δ-Aβ42. The spectra of Aβ are shown after subtraction
of the background spectrum in the presence of PBN without Aβ.
NumbersinparenthesesrepresentrelativeintegralintensitiesofESR
signals, where the intensity of Aβ40 was taken as 1.0.
37◦C.Theanti-N-terminusofAβ antibody,82E1,(Immuno-
Biological Laboratories Co., Ltd., Gunma, Japan) was used at
1μg/mL as the primary antibody.
2.5. CD Spectrometry. Each Aβ was dissolved in 0.1%
NH4OH at 250μM and diluted 10 times with 50mM
phosphate buﬀer (pH 7.12). The procedure was described
elsewhere [16].
2.6. ESR Spectrometry. A reliable method for estimating the
ability of Aβ (100μM) to produce radicals using ESR was
developed by Butterﬁeld’s group [18]. ESR spectrometry
was performed on an EMX ESR spectrometer (Bruker
BioSpin K.K., Karlsruhe, Germany) at room temperature, as
described elsewhere [19].
2.7.EstimationofCellSurvival. Toevaluatetheneurotoxicity
of Aβ using an MTT assay, we used undiﬀerentiated PC12
cells, which have the potential to diﬀerentiate into neural
cells, are sensitive to Aβ, and are generally used for detecting
neurotoxicity as a neurotoxicity model [20]. The experimen-
tal procedure was described elsewhere [15].
2.8. Preparation of Primary Culture and Estimation of Cell
Survival. Near-pure neuronal cultures were obtained from
the cerebral cortices of fetal rats (17–19 days of gestation)
as described [21, 22]. Cultures were maintained in Eagle’s
MEM supplemented with 10% heat-inactivated fetal bovine
serum or 10% heat-inactivated horse serum at 37◦Ci na
humidiﬁed5%CO2 atmosphere.Topreventtheproliferation
of nonneural cells, 10μM cytosine β-arabinofuranoside
hydrochloride was added after 5 days of plating. In all
experiments mature cells used after 11–13 days in vitro.
Animalsweretreatedinaccordancewiththeguidelinesofthe
KyotoUniversityanimalexperimentationcommitteeandthe
guidelines of the Japanese Pharmacological Society.
Each Aβ was dissolved in 0.02% NH4OH at 200μM
and diluted on ice immediately before treatment. After
48hr treatment, neurotoxicity was evaluated by lactate
dehydrogenase (LDH) release assay and MTT assay.
2.9. Long-Term Potentiation. Field excitatory postsynaptic
potentials (fEPSPs) were recorded from the CA1 region
of rat hippocampal slices (Wistar rats, male, 6 weeks
old) by electrically stimulating the Schaﬀer collateral [23].
Hippocampal slices were soaked in E22Δ-Aβ40, E22Δ-Aβ42,
and E22P-Aβ42 solution [20μg/200mL phosphate-buﬀered
saline (PBS)] before high-frequency stimulation (5 trains
consisted of four 100-Hz pulses with an intertrain interval of
200ms). fEPSPs were measured in the presence and absence
of each Aβ.
3. Results and Discussion
3.1. Aggregative Ability of E22Δ Mutants. E22Δ-Aβ40 and
E22Δ-Aβ42 were examined for their aggregative ability by
a sedimentation assay: HPLC analysis after centrifugation
of each Aβ solution. Both E22Δ-Aβ40 and E22Δ-Aβ42
aggregated at a velocity similar to Aβ42, while Aβ40 hardly
aggregated even after 24-hr incubation (Figure 1(a)). This
suggests that the ability to form aggregates of both E22Δ-
Aβ40 and E22Δ-Aβ42 would be comparable to that of
Aβ42 though soluble Aβ assemblies (oligomers) could not
be distinguished from high-molecular weight ﬁbrils in this
assay condition (centrifugation: 20,000g × 10min). In the
Th-T assay, which can estimate the β-sheet structure in Aβ
aggregates[17],E22Δ-Aβ40showedhigherﬂuorescencethan
Aβ40. In contrast, the maximum ﬂuorescence of E22Δ-Aβ42
did not exceed that of Aβ42, although the velocity of E22Δ-
Aβ42 showing ﬂuorescence was slightly higher than that
of Aβ42 (Figure 1(b)). These data suggest that the E22Δ
mutation accelerates the aggregation of Aβ.
Western blotting was carried out to estimate accurately
the oligomerization state of Aβ.E 2 2 Δ-Aβ42 formed trimers
exclusively, but E22Δ-Aβ40 produced dimers immediately
after incubation (Figure 1(c)), as did the cases in the paper
by Tomiyama et al. [14]; however, our Th-T assay results do
not coincide with their results [14]; under Tomiyama’s con-
ditions, both mutants showed almost no ﬂuorescence, even
after 7 days. This discrepancy of the Th-T test may be due
to the diﬀerent conditions to make aggregates, presumably
resulting in the generation of oligomers containing a β-sheet
structure, as Ishii and coworkers suggested [24, 25].
3.2. Secondary Structure of E22Δ Mutants. To investigate the
secondary structure of E22Δ-Aβ40 and E22Δ-Aβ42, their
CD spectra were measured. In the control experiment using
Aβ42 (Figure 2(c)), the positive peak at 200nm and the
negative peak at 220nm gradually increased during the 48-
hr incubation, suggesting that transformation of the random
organization into a β-sheet structure occurred, while Aβ40
remained mainly random (Figure 2(a)). In contrast, E22Δ-
Aβ42 formed a β-sheet-rich structure immediately after dis-
solution (Figure 2(d)). The velocity of the transformation of
E22Δ-Aβ40 was also higher than that of Aβ42 (Figure 2(b)).International Journal of Alzheimer’s Disease 5
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Figure 4: Neurotoxicity of Aβ40, Aβ42, E22Δ-Aβ40, E22Δ-Aβ42, and E22P-Aβ42 with the indicated concentration (1, 2, 5, 10, and 20μM)
using primary rat cortical neuronal cell cultures after 48-hr incubation at 37◦C. Data are expressed as the mean ± s.e.m. ∗P<. 05 versus
vehicle, ∗∗P<. 01versus vehicle. Veh: vehicle.
TheseresultssuggestthattheE22Δmutationinducesβ-sheet
transformation to form Aβ oligomers under our condition.
3.3. Radical Production by E22Δ Mutants. Our previous
studies suggested that the radical productivity of Aβ42
mutants at position 22 such as E22P-, E22K-, E22Q-, and
E22G-Aβ42 correlated with their aggregative ability and
neurotoxicity [7]. To investigate the eﬀect of E22Δ mutation
in Aβs on the radical-generating activity, ESR was measured
using phenyl-N-tert-butylnitrone (PBN) as a spin-trapping
reagent (Figure 3). ESR signals of E22Δ-Aβ40 were twice
more potent than those of Aβ40, and E22Δ-Aβ42 also
showed slightly stronger signals than Aβ42. The radical
productivity of the E22Δ-Aβs correlated basically with their
ability to form oligomers and a β-sheet structure (Figures
1(c), 2).
3.4. Neurotoxicity of E22Δ-Aβsi nP r i m a r yR a tC o r t i c a l
Neuronal Cell Cultures. Having demonstrated that E22Δ
mutation enhanced the β-sheet structure and radical pro-
ductivity, we assessed the eﬀect of this mutation on the
neurotoxicity in primary rat cortical neuronal cell cultures
by LDH and MTT assay (Figure 4). Treatment of the
neurons with 1–20μM of wild-type Aβ42 for 2 days induced
neurotoxicity in a dose-dependent manner in the LDH test
(Figure4(a),left),inwhichthereleasedLDHofthedamaged
cells (mainly neurons) was measured in the medium. E22P-
Aβ42 with a turn at positions 22, and 23 induced stronger
damagetotheneuronsthanwild-typeAβ42;cellviabilitywas
less40%at20μM(Figure4(a),right).Ontheotherhand,the
diﬀerence in cell viability between the vehicle and wild-type
Aβ42 did not reach a signiﬁcant level in the MTT assay even
at 20μM (Figure 4(b), left). The cell viability of E22P-Aβ42
inMTTwasalsoabout50%at20μM.IntheMTTassay,total
cells containing neurons, astrocytes, and microglia damaged
by Aβs were counted. Since the neurons are more sensitive
to damage than astrocytes or microglia in the primary cell
cultures [26], the “neurotoxicity” estimated by the LDH test
is often stronger than that evaluated by the MTT test.
It is worth noting that E22Δ-Aβ40 and E22Δ-Aβ42 as
wellasAβ40at20μMfailedtoshowneurotoxicityagainstthe
primary cultures both in the LDH and MTT tests (Figure 4).
These results are consistent with those reported by Takuma6 International Journal of Alzheimer’s Disease
et al.; the neurotoxicity of E22Δ-Aβ42 was very weak against
mouse neuroblastoma Neuro-2a and human neuroblastoma
IMR-32 [15]. In our MTT test using rat neuroblastoma
PC12 cells, the IC50 of E22Δ-Aβ42 and wild-type Aβ42 was
4.6 ± 1.1μMa n d0 .65 ± 0.11μM, respectively, showing that
E22Δ-Aβ42 was signiﬁcantly less toxic than wild-type Aβ42.
The neurotoxicity of E22Δ-Aβ40 (IC50 = 10 ± 1.0μM) was
weak as expected, but slightly stronger than that of Aβ40
(IC50 = 20 ±1.0μM).
3.5. Synaptotoxicity of E22Δ Mutants. Selkoe and coworkers
suggested that Aβ dimers are the smallest synaptotoxic
species inhibiting the LTP in the pathogenesis of AD and
that plaque cores are largely inactive but sequester and
release dimers [27]. Tomiyama et al. reported the more
potent inhibition of LTP by E22Δ-Aβ42 than by wild-type
Aβ42 [14]. We tested the inhibition of LTP by E22Δ-Aβ40
using rat hippocampal slices. Figure 5 shows that E22Δ-
Aβ40 is not such a potent inhibitor of LTP as E22Δ-Aβ42,
whose inhibitory potency was stronger that of than wild-
type Aβ42, as Tomiyama et al. reported [14]. This coincides
with the previous datas that the 42-mer Aβ showed more
potent neurotoxicity than 40-mer Aβ [13]. Notably, E22P-
Aβ42, which can more readily form a toxic conformer
with a turn at positions 22 and 23 than wild-type Aβ42
[11], inhibited the LTP more strongly than E22Δ-Aβ42 at
an almost undetectable level after 60min (Figure 5(b)).
This suggests that the conformation at positions 22 and 23
of E22P-Aβ42 might be similar to that of E22Δ-Aβ42 at
positions 21 and 23.
3.6. Relevance of E22Δ Mutation to Turn-Induced Neuro-
toxicity. The present results suggest that E22Δ mutation
in Aβ accelerates the transformation of a random form
into a β-sheet structure (Figure 2) and radical productivity
(Figure 3) but does not increase neurotoxicity in primary
rat cortical neuronal cell cultures (Figure 4). E22Δ-Aβ42
synthesized in our laboratory showed the signiﬁcant forma-
tion of oligomers (Figure 1) and synaptotoxicity (Figure 5),
as reported by Mori and coworkers [14]. In addition,
E22P-Aβ42 inhibited LTP more severely than E22Δ-Aβ42
(Figure 5). We previously reported that E22P-Aβ42, with a
turn at positions 22 and 23 as a Pro-X corner (X: variable
amino acid residue) [28], could form signiﬁcant oligomers
[11]w i t haβ-sheet-rich structure [16] and radicals to result
in potent neurotoxicity with the formation of radicals [7];
therefore, E22Δ-induced synaptotoxicity might be in part
related to turn-induced radical formation. This implies that
conformationalchangeinE22Δ-AβissimilartothatinE22P-
Aβ42, but is not the same since E22Δ-Aβ42 exhibited no
neurotoxicity, unlike E22P-Aβ42 and wild-type Aβ42.
It should be noted that the eﬀects of E22Δ mutation
on the physicochemical properties of Aβ40 are signiﬁcantly
higher than those of Aβ42. This tendency is similar to cases
of other CAA or FAD mutant Aβs. We previously reported
a comprehensive study on the aggregation, neurotoxicity,
and secondary structure of Aβ mutants at positions 21–23
(A21G, E22G, E22Q, E22K, and D23N) [13]. Since Aβ40
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is secreted in neurons about nine times more abundantly
than Aβ42 [3], in some cases Aβ40 may play a critical
role in the pathogenesis of CAA or FAD. In addition, the
E22Δ mutant of Aβ40 [14] as well as the CAA- or FAD-
related Aβ40 mutants at positions 21, 22, and 23 have been
reported to be more resistant than wild-type Aβ40 against
degradation by insulin-degrading enzyme [29]; however, it
remains controversial whether E22Δ is a familial type of AD
or AD-type dementia.
Mori,Tomiyama,andcoworkersimpliedtheintracellular
accumulation of Aβ oligomers using cultured cells [30]a n d
theirowndevelopedmousemodel[31]withE22Δmutation.
This mutation also caused apoptosis induced by stress in
the endoplasmic reticulum [30]. Quite recently, we proposed
the involvement of a turn at positions 22 and 23 of Aβ in
intracellular amyloidosis [32]. Thus, the increase of radical
productivity by E22Δ mutation is in good agreement with
the turn-induced oxidative stress of Aβ42 [7], presumably
viatheinterplaybetweenTyr10andMet35[12].Thedeletion
mutation of the residue at position 22 might promote Tyr10
in close proximity to the sulfur atom of Met35, inducing the
eﬀective production of radicals.
4. Conclusion
In summary, E22Δ-Aβ42 eﬀectively induced the transfor-
mation of a random form to a β-sheet structure and the
formation of radicals accompanied with oligomerization.
However, the molecular mechanism of the pathology of AD
of E22Δ-Aβ42 might be diﬀerent from that of wild-type
Aβ42 since E22Δ-Aβ42 showed more potent synaptotoxicity
but weaker neurotoxicity than wild-type Aβ42.
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